Pfizer Inc. may have to overcome a lack of improvement on an endpoint typically not required for approval if it is to gain a psoriatic arthritis indication for Xeljanz (tofacitinib).
If it gets the expanded indication, the Janus associated kinases (JAK) inhibitor would be the first in its class with...